Terminated PHASE2 INTERVENTIONAL 2-arm NCT00951379

Pioglitazone for Oral Premalignant Lesions

Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions an Inter-consortium Collaborative Study

Sponsor: National Cancer Institute (NCI)

Conditions Oral Leukoplakia

Interventions Pioglitazone hydrochloride laboratory biomarker analysis placebo

Updated 7 times since 2017 Last updated: Mar 29, 2016 Started: Feb 28, 2010 Primary completion: Mar 31, 2014 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to slow accrual.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

A PHASE2 clinical study on Oral Leukoplakia, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Boston, United States , Buffalo, United States , Charleston, United States , Houston, United States , Iowa City, United States , Madison, United States , Milan, Italy , Minneapolis, United States , New York, United States and 1 more location